THE PROBLEM: Novel technology platform could be used across a wide range of rare diseases, so executive team and board want an independent, evidence-based view of commercial opportunity to complement the scientific analysis. THE SOLUTION: Interviews with KOL physician-scientists to understand unmet need and applicability of technology to targets, detailed pipeline analysis, market modeling and